Covid-19 vaccines: In the rush for regulatory approval, do we need more data?

Article highlights that following initial rollout under emergency authorisation, manufacturers are now pursuing full regulatory approval. It covers the implicationsand calls for ensuring a robust review rather approval simply as a mechanism to convince people of safety.

Source:

British Medical Journal